Sanz S, Pucilowska J B, Liu S, Rodríguez-Ortigosa C M, Lund P K, Brenner D A, Fuller C R, Simmons J G, Pardo A, Martínez-Chantar M-L, Fagin J A, Prieto J
Division of Hepatology and Gene Therapy, Clinica Universitaria and Medical School, Center for Applied Medical Research (CIMA), University of Navarra, 31008, Pamplona, Spain.
Gut. 2005 Jan;54(1):134-41. doi: 10.1136/gut.2003.024505.
BACKGROUND/AIM: Hepatic stellate cells (HSCs) express alpha-smooth muscle actin (alphaSMA) and acquire a profibrogenic phenotype upon activation by noxious stimuli. Insulin-like growth I (IGF-I) has been shown to stimulate HSCs proliferation in vitro, but it has been reported to reduce liver damage and fibrogenesis when given to cirrhotic rats.
The authors used transgenic mice (SMP8-IGF-I) expressing IGF-I under control of alphaSMA promoter to study the influence of IGF-I synthesised by activated HSCs on the recovery from liver injury.
The transgene was expressed by HSCs from SMP8-IGF-I mice upon activation in culture and in the livers of these animals after CCl4 challenge. Twenty four hours after administration of CCl4 both transgenic and wild type mice showed similar extensive necrosis and increased levels of serum transaminases. However at 72 hours SMP8-IGF-I mice exhibited lower serum transaminases, reduced hepatic expression of alphaSMA, and improved liver morphology compared with wild type littermates. Remarkably, at this time all eight CCl4 treated wild type mice manifested histological signs of liver necrosis that was severe in six of them, while six out of eight transgenic animals had virtually no necrosis. In SMP8-IGF-I mice robust DNA synthesis occurred earlier than in wild type animals and this was associated with enhanced production of HGF and lower TGFbeta1 mRNA expression in the SMP8-IGF-I group. Moreover, Colalpha1(I) mRNA abundance at 72 hours was reduced in SMP8-IGF-I mice compared with wild type controls.
Targeted overexpression of IGF-I by activated HSCs restricts their activation, attenuates fibrogenesis, and accelerates liver regeneration. These effects appear to be mediated in part by upregulation of HGF and downregulation of TGFbeta1. The data indicate that IGF-I can modulate the cytokine response to liver injury facilitating regeneration and reducing fibrosis.
背景/目的:肝星状细胞(HSCs)表达α-平滑肌肌动蛋白(αSMA),在受到有害刺激激活后会获得促纤维化表型。胰岛素样生长因子I(IGF-I)已被证明在体外可刺激肝星状细胞增殖,但有报道称,给予肝硬化大鼠IGF-I可减轻肝损伤和纤维化。
作者使用在αSMA启动子控制下表达IGF-I的转基因小鼠(SMP8-IGF-I),研究活化的肝星状细胞合成的IGF-I对肝损伤恢复的影响。
SMP8-IGF-I小鼠的肝星状细胞在培养中被激活后以及在这些动物经四氯化碳攻击后的肝脏中均表达转基因。给予四氯化碳24小时后,转基因小鼠和野生型小鼠均出现相似的广泛坏死,血清转氨酶水平升高。然而,在72小时时,与野生型同窝小鼠相比,SMP8-IGF-I小鼠血清转氨酶水平较低,肝脏αSMA表达降低,肝脏形态改善。值得注意的是,此时所有8只经四氯化碳处理的野生型小鼠均表现出肝坏死的组织学迹象,其中6只严重,而8只转基因动物中有6只几乎没有坏死。在SMP8-IGF-I小鼠中,强大的DNA合成比野生型动物更早发生,这与SMP8-IGF-I组中HGF产生增加和TGFβ1 mRNA表达降低有关。此外,与野生型对照相比,SMP8-IGF-I小鼠在72小时时Colα1(I)mRNA丰度降低。
活化的肝星状细胞靶向性过表达IGF-I可限制其活化,减轻纤维化,并加速肝再生。这些作用似乎部分是由HGF的上调和TGFβ1的下调介导的。数据表明,IGF-I可调节对肝损伤的细胞因子反应,促进再生并减少纤维化。